

INFORMATION RELEASE - 20 MAY 2008

EFFICACY AND SAFETY OF CHAPERONIN 10 IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS: EVIDENCE OF UTILITY BEYOND A SINGLE INDICATION

In 2006 CBio successfully completed three Phase II intravenous dosing clinical trials of XToll[®]. Data generated from the completed intravenous dosing Phase IIa rheumatoid arthritis clinical trial was accepted for publication in international medical journal The Lancet in September 2006 (Vanags et al, Lancet 2006; 368: 855-63). Findings through peer-review were that XToll[®] showed evidence of clinical effect in rheumatoid arthritis patients with well-established disease, while being well tolerated.

In its current issue, Archives of Dermatology has published a research letter recognising the therapeutic benefits of XToll[®] in patients with moderate to severe plaque psoriasis (Arch Dermatol, 2008; 144: 683-685).

This exploratory study shows preliminary evidence of short-term efficacy and safety and decreased release of TNF- α and IL-1 β , significant in inflammation. Lack of placebo is an acknowledged limitation of this pilot study, however the results raise the possibility that Cpn10 may modulate inflammation in a range of therapeutic areas.



Jason Yeates
Managing Director & CEO

About CBio Limited

CBio Limited is an Australian unlisted public biopharmaceutical company established in 2001 to develop technologies for the treatment of autoimmune and inflammatory diseases. CBio's lead product is XToll[®]. XToll[®], or recombinant chaperonin 10 (Cpn10), is a modified version of the naturally occurring protein chaperonin 10. For further information www.cbio.com.au